Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
The two immunotherapy strategies showed no significant differences in OS and PFS. Of note, more pts were on Avelumab treatment at the data cut-off. AEs were similar in the two groups. Further investigation and follow-up are warranted to gain definitive conclusions on optimal mUC management in the era of immunotherapy and immunoconjugates.
Authors
- Sara Merler (ORCID: https://orcid.org/0000-0002-8691-6284)
- Davide Pastorelli
- Sarah Pafumi
- Cristina Lorenzi (ORCID: https://orcid.org/0000-0002-3324-1359)
- E Durante
- Nicola Inzerilli
- Michele Stanislaw Milella (ORCID: https://orcid.org/0000-0002-5939-8549)
- Silvia Palmerio (ORCID: https://orcid.org/0000-0001-8874-3711)
- Francesca Zacchi (ORCID: https://orcid.org/0000-0002-7448-7822)
- Mattia Pellicciari
- Giulia Lorenzoni (ORCID: https://orcid.org/0000-0003-1771-4686)
- Irene Torresan
- Anna Sordo
- Andrea Zivi
- Ester Tasselli
Institutions
- University of Verona (IT)
- University of Padua (IT)
- Azienda Ospedaliera Universitaria Integrata Verona (IT)
- Casa di Cura Villa Garda (IT)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-02-21
- DOI
- https://doi.org/10.3389/fonc.2025.1532421
- Citations
- 2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.01